. Koca Et Al. , "Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen," Kafkas J Med Sci , vol.7, no.1, pp.53-59, 2017
Koca, . Et Al. 2017. Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas J Med Sci , vol.7, no.1 , 53-59.
Koca, ., Demir, D., Ozdemir, ., Akdeniz, H., & Kurt, ., (2017). Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen. Kafkas J Med Sci , vol.7, no.1, 53-59.
Koca, Et Al. "Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen," Kafkas J Med Sci , vol.7, no.1, 53-59, 2017
Koca, Dogan Et Al. "Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen." Kafkas J Med Sci , vol.7, no.1, pp.53-59, 2017
Koca, . Et Al. (2017) . "Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen." Kafkas J Med Sci , vol.7, no.1, pp.53-59.
@article{article, author={ Dogan Koca Et Al. }, title={Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen}, journal={Kafkas J Med Sci}, year=2017, pages={53-59} }